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ABSTRACT 
Introduction: Cervical cancer is caused by persistent infection with high-risk Human 
Papilloma Virus (HPV) and is a leading cause of cancer deaths in South African women 
aged 15-65years. We estimated prevalence of abnormal (Atypical squmous cells of 
unknown significance to invasive cervical cancer) cervical cytology and associated co-
factors in 18-35-year old women who tested negative for Human Immuno deficiency 
Virus (HIV). 
  
Method: This cervical lesion study was secondary analysis of data collected during a 
Microbicide Feasibility Study (MFS). MFS recruited 1100 women from public health 
care facilities. Women were interviewed and socio-demographic, sexual behaviour and 
clinical information was collected. If HIV negative, cervical and vaginal swabs were 
collected for Pap smear and laboratory testing for sexually-transmitted infections (STI). 
For the cervical lesion study, 808 women were eligible and 752 were enrolled in the 
study. Associations with abnormal cervical cytology were analysed using multiple 
logistic regression, and were reported as adjusted odds ratio (AOR) with a 95% 
confidence interval (CI). 
 
Results: We analysed 570 cytology specimens. Prevalence of abnormal cervical cytology 
was 6.7% (95% CI 4.8-9.0). Women who had an abnormal cervical cytology result were 
more likely than those with normal cytology results to report abnormal vaginal discharge 
(OR 2.33; 95% CI 1.07-5.06; p=0.03). They were also more likely to have more than one 
child (OR 2.21; 95% CI 1.00-4.87; p=0.05). 
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Discussion and conclusion: Our study showed that LSIL is common in this younger age 
group. Because HPV infection and thus abnormal cervical cytology are high among the 
younger population, this result is not unexpected. Since most LSIL regress naturally, our 
data support the current South African screening protocol for cervical cancer. 
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1.0  INTRODUCTION 
Burden of cervical cancer 
Cervical cancer is the second most common cancer in women throughout the world, and 
the most common cancer in women in low and middle income countries. About 371, 000 
new cases of cervical cancer are diagnosed in the low and middle income countries each 
year (Parkin, 2005). Of the estimated 300 000 cervical cancer deaths annually, about 80% 
are from low and middle income countries (Parkin, 2005). According to the South 
African National Cancer Registry (NCR), black females (aged 0-74 years) had a lifetime 
probability of developing cervical cancer of 4.34 (1 in 23) in 1997 compared with 
American women (all races), who had a probability of 0.78 (1 in 129) (Mqoqi, 2003 and 
American Cancer Society, 2001). From figure 1, cervical cancer is leading cause of 
cancer deaths in women in South Africa. 
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Figure 1: Top five cancer-related mortality rates in women, worldwide. (Ferlay, 2004) 
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Cervical cancer incidence increases sharply with age among South African women. In 
2002, age-specific incidence rates (per 100 000 women per year) of cervical cancer was 
19.6, 104 and 118 for women in the age groups: 15-44years, 45-54years and 55-64years. 
These rates were high compared with: 9, 44 and 50 for women in the world in the age 
groups: 15-44years, 45-54years and 55-64years. (Ferlay, 2004). The above cancer 
statistics highlight high levels of disparity in the burden of disease between high and low 
to middle income countries.  
 
Squamous cell carcinoma 
Squamous cell carcinoma accounts for approximately 80% of all cervical cancers. The 
second most common form of cervical cancer is adenocarcinoma (Dolinsky, 2002). Due 
to hormonal, physical and infectious influences, the cervical surface epithelia change 
throughout a woman’s lifetime. This change may promote or interrupt cervical diseases 
development. Some of the changes include cervical ectopy, which exposes the 
transformation zone to infections. (Coombs, 2003). The transformation zone is a site of 
cell-structure change (from columnar to squamous cells) and lies just inside the cervix os, 
as shown in figure 2a. In cervical ectopy, the transformation zone becomes exposed. 
 
Human papillomavirus (HPV) in the aetiology of cervical cancer 
HPV is a double-stranded DNA-virus with a closed circular genome. It is a member of 
the Papovaviridae family. Over 100 HPV sub-types have been characterized molecularly 
and about 40 can infect the genital tract and can cause cancer or warts. (Bosch, 2005). 
HPV is a common sexually-transmitted infection (STI). Approximately 50% of sexually-
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active men and women aged 15-49 years have been infected with HPV at some point in 
their lives (Schiffman, 2003 and Manhart, 2002).  
 
 
 
a) Transformation zone (Cancerhelp, 2008)                       b) Cervix (Medlineplus, 2008) 
Figure 2: Diagram showing (a) transformation zone close-up & (b) structure of the cervix 
 
Almost all cases of cervical cancer are associated with high-risk HPV (HR-HPV). A 
matched case-control study found a 99.7% prevalence of HPV DNA in cervical cancer 
cases (Walboomers, 1999). HPV-16 and -18 cause almost half of all cervical cancers 
(Schiffman, 2003). Other high risk sub-types include HPV-45, -31, -33, -52, -58 and -35 
(Munoz, 2006). Oncogenic HPV sub-types are thought to cause the production of two 
proteins, E6 and E7. These proteins turn off some host tumour-suppressor genes 
(American Cancer Society, 2005a). Turning off of these genes may allow uncontrolled 
growth of cells lining the cervix. 
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HPV-16 and HPV-18 have distinguishing biochemical and biological activities compared 
to low-risk genital HPV types. For example: HPV-16 and HPV-18 oncoprotiens E6/E7 
bind p53/pRB protein, respectively, with a higher affinity than the corresponding LR-
HPV proteins and an enhanced potential of HPV-16 and HPV-18 E2 proteins to activate 
transcription. (Pablo, 2005) 
 
Natural history of HPV infection 
HPV is a necessary, but not a sufficient cause of cervical cancer. As shown in figure 3 
below, about half of HPV infections are transient and are cleared in less than two years 
(Claeys, 2002). Also, about 60% of low grade intraepithelial lesions may regress to 
normal. If HPV persists, cervical lesions form and may progress and develop into 
invasive cancer (Schiffman, 2003; Manhart, 2002; Munoz, 1997). 
 
 
Figure 3: Natural history of cervical carcinogenesis (Schiffman, 2003 & Munoz, 1997). 
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Co-factors in the development of cervical cancer 
While HPV is primary aetiological agent in cervical cancer, additional factors have been 
implicated in HPV persistence and progression and the development of cervical cancer. 
These factors include: 
 
Age 
Because cervical cancer takes many years to develop (see figure3), it is generally more 
common among older women. A multi-center prevalence survey was conducted in South 
Africa, to describe age-specific prevalence rates of cervical cancer in South African 
women presenting for screening. Results of this survey showed that cervical cancer is 
common among older women. Women with LSIL (2.42% of women screened) had an 
average age of 33.1 years, while women with HSIL (1.8%) had an average age of 37.97 
years and women with invasive cancer (0.47%) had an average of 51.3 years. These age 
differences were statistically significant (Fonn, 2002). 
  
In other settings, cervical cancer may develop at younger ages (<35 years) and dysplasia 
may progress more quickly to invasive disease (Jennings, 1992). Lancaster (1999) 
studied 10 000 Papanicolaou (Pap) smears from Ka-Ngwane (South Africa) and found 
that 78% of CIN III cases were 40 years old or younger. A descriptive case series in a 
population of sexually-active adolescents in New York found an increase in the 
prevalence of benign cellular changes from 8.7% in 1982-3 to 20.1% in 1992-3; 
prevalence OR 2.7; 95% CI 1.9-3.8) (Mangan, 1997). 
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There is evidence showing that regression or progression of pre-invasive cervical cancer 
is greatly influenced age of the patient. A modelling study was conducted, to assess 
regression of pre-invasive cervical cancer, using data from British Columbia Pap smear 
screening programme. This study showed that for women aged 18-34 years, 84% (95% 
CI 76-92%) of the new lesions will regress spontaneously. This regression rate was 
significantly reduced to 40% for women over the age of 34 years. (van Oortmarssen, 
1991) 
 
Genetic factors 
The genetic background of the host may influence persistence of HPV infection. Among 
genetic factors thought to be involved in the susceptibility to squamous cell cervical 
cancer and disease outcome, two have been intensely investigated. These are the 
polymorphic genes of the major histocompatibility complex (MHC (viz. the human 
leukocyte antigen (HLA) complex)), as well as a particular polymorphism in the p53 
gene (Maciag, 1999). MHC genes encode proteins involved in antigen presentation to T-
cells (both CD4+ and CD8+ T-cells) and p53 is a tumor suppressor gene that regulates cell 
proliferation. In a case control study conducted in Montreal by Ades (2008), the HLA 
variant (B7-DRB1*1501-DQB1*0602 haplotype) was associated with a 83% reduction in 
risk of HSIL among HPV-16 and HPV-18 positive subjects (OR 0.17; 95% CI 0.05-
0.54). Similar associations were also observed among Southern Chinese women (Chan, 
2007).  
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Brown (2008) carried out series of experiments to study the interaction between HPV-16 
DNA components and host p53. Their results suggested that p53 down-regulated HPV-16 
DNA replication via the E2 protein. HPV-host genetic interaction depends, to a large 
extent, on the population and the HPV subtype being studied. 
  
Gynaecological factors 
High parity is thought to increase the risk of developing cervical cancer through the 
maintenance of the transformation zone on the exocervix for many years. This may 
facilitate exposure to HPV. Hormonal factors may also be involved in this process. 
(Munoz, 2006). A case-control study conducted in Mali, among 82 invasive cancer cases 
and 97 controls, showed that high parity and poor genital hygiene conditions were the 
main co-factors for cervical cancer in this population (Bayo, 2002). More recently, in a 
meta-analysis of 10 case-control studies, HPV-positive women with more than one child 
were at a higher risk of squamous-cell carcinoma of the cervix compared to those with no 
children, (OR 2.3; 95% CI 1.6-3.2). Women with more than six full term pregnancies 
were even much more likely, than those with no full-term pregnancies, to have 
squamous-cell carcinoma of the cervix (OR 3.8; 95% CI 2.7-5.5). Younger age at first 
full-term pregnancy was independently associated with an increased risk of ICC (risk 
ratio (RR) 1.07; 95% CI 1.06-1.09) for each decline in year. (Munoz, 2002). 
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Hormonal contraceptives 
The use of hormonal contraceptives changes hormone levels which may disturb the 
normal environment and facilitate cervical infection. In a systematic review of 28 studies, 
together including 12,531 women with cervical cancer, oral contraceptive (OC) users had 
a greater risk of developing cervical cancer (Odds ratio (OR) 2.5; 95% CI 1.6-3.9) 
compared to non-users (OR 1.1; 95% CI 1.1-2.2) (Smith, 2003). 
 
In 2002, the International Agency for Research on Cancer (IARC) conducted a meta-
analysis of ten case control studies. This analysis was restricted only to women with a 
positive HPV DNA test. The risk of cervical cancer was higher in women who had used 
OC for ten or more years compared with never-users (RR 4.03; 95% CI 2.09-8.02) 
(Moreno, 2002). Because of HPV DNA assay inclusion, this analysis provided stronger 
evidence of an association between prolonged hormonal contraceptive use and risk of 
cervical cancer.  
 
However, a case-control study conducted in South Africa, on 524 invasive cervical 
cancer cases and 1541 controls (including 254 HPV-positive controls) found no evidence 
suggesting that either injectable progestin-only or combined estrogen/progestogen OC 
increase the risk of clinically evident invasive cancer of the cervix. Progestin-only users 
were no more likely, than combined estrogen/progestogen OC-users, to have invasive 
cervical cancer, (adjusted (A) OR 1.0; 95% CI 0.8-1.3 versus AOR 0.8; 95% CI: 0.7-1.1) 
(Shapiro, 2003). Behavioural differences between OC users and other women may 
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confound the relationship and make it difficult to study the role of OC use in genital tract 
diseases. 
 
Co-infection with HIV 
Because HIV attacks the immune system, co-infection with HR-HPV and HIV 
undermines the ability of the immune system to fight the HPV.  In this way, HIV may 
cause HPV persistence or speed up progression to invasive cervical cancer (ICC). This 
synergy is of concern especially in Southern Africa where HIV prevalence is high and 
anti-retroviral therapy (ART) is not widely accessible.  
 
A case control study (138 cases and 138 controls) conducted in Tanzania found that HIV-
1 positive women were more likely to have ICC compared with HIV-1 negative women 
(OR 2.9; 95% CI 1.4-5.9). Another case control study conducted in the Western Cape 
(South Africa) observed a strong association between squamous intraepithelial lesions 
(SIL) and co-infection with HIV and high risk HPV compared to women with neither 
infection (AOR 41.3; 95% CI 18.8-90.5). But there was no excess risk of invasive 
cervical cancer (ICC) (AOR 1.17; 95% CI 0.75-1.85). (Moodley, 2006). Sitas (2000) 
examined the relationship between HIV-1 and a number of cancer types that are common 
in South Africa. Their study focused in the Johannesburg area and used case control 
design. Women who were HIV positive were more likely, than those who were HIV 
negative, to have cervical cancer (OR 1.6; 95%CI 1.1-2.3).  
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Adam (2008) followed up a cohort of 575 women attending the colposcopy clinic at 
Chris Hani Baragwanath Hospital, Soweto, South Africa, to investigate clinical predictors 
of persistent cytological abnormalities in women who had had a large loop excision of the 
transformation zone (LLETZ). Half (49.4%) of the patients had persistent abnormal 
smears six months after LLETZ treatment. Of those patients who had persistent 
abnormality, 64% were HIV positive and 13% HIV negative, p<0.001. Of those patients 
who were HIV positive and had persistent cytological abnormality, 56% had CD4 count 
<200 versus 24% with CD4 count >499, p<0.001. Since highly active antiretroviral 
therapy (HAART) has recently been publicly-introduced in South Africa, it is unclear as 
to what effect this will have on excess mortality due cervical cancer.  
 
Sexual behaviour and STI 
Other factors which increase a woman’s risk of getting HPV infection include having sex 
at an early age, having many sexual partners (lifetime or concurrent) and having sex with 
an uncircumcised male (Castellsague, 2001). These factors are all indicators of higher 
risk sexual behaviour and may be markers for infection with an STI. 
 
A study of 1000 women seeking STI services in inner city Baltimore found evidence 
linking Chlamydia trachomatis (CT) to abnormal Pap smear (OR 2.04; 95% CI 1.0-4.15) 
(Kanno, 2005). In a longitudinal cohort study carried out to determine whether 
gynaecological infections other than HPV are related to the risk of cervical cancer or not 
found that both Trichomona vaginalis (TV) and positive Herpes simplex virus-2 (HSV-2) 
serology were predictors of cervical neoplasia, with standardized incidence ratio (SIR) of 
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6.4 (95% CI 3.7-10.0) and 12.0 (95% CI 2.4-34.0) respectively (Viikki, 2000). It is 
unclear if other agents operate independently from HPV or whether these associations are 
merely confounded by sexual behaviour. Other studies have found no evidence of 
association between cervical cancer and Herpes simplex virus-2 (RR 0.9; 95%CI 0.6-1.3) 
(Lehtinen, 2002), Chlamydia trachomatis (p=0.4) (Ghazal-Aswald, 2006) and again 
Chlamydia trachomatis (p>0.05) (Takac, 1999). These latter four studies should be 
interpreted with caution though since they have some methodological weaknesses which 
may diminish their power to detect association between these STI and cervical 
abnormality. These weaknesses included small sample sizes and use of Chlamydia 
trachomatis test kit with lower sensitivity in a low-prevalence population. 
 
Cervical inflammation and inflammatory response 
Evidence of an association between specific STI and cervical cancer is inconclusive. This 
has lead to continued search for other HPV cofactors in the development of cervical 
cancer. Tjiong (1999) studied cervicovaginal washings to establish whether inflammatory 
cytokines could be found in relation to cervical neoplasia. The concentrations of 
interleukin-6 (IL-6) and interleukin-8 (IL-8) increased with severity of cervical neoplasia. 
 
Inflammation (and smoking) increase reactive oxygen species (oxygen-related free 
radicals), reduce antioxidant activity and adversely affect natural history of HPV 
infections.  Free radicals cause genotoxic damage of host DNA (Castle, 2003) and HPV-
infected cells can not effectively clear these cells. There is no evidence to suggest that 
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HPV alone induce inflammatory response (Castle, 2001). So, inflammatory response 
could be confidently linked to HPV cofactors rather than the HPV infection itself. 
 
Smoking 
Cigarette contains carcinogenic ingredients and cigarette smoking is linked to several 
cancers, notably as a cause of lung cancer. Cigarette smoking may reduce 
immunoresponse in the cervix, affect female hormone metabolism or cause direct genetic 
damage. A case-control study carried out in the USA among women exposed to 
oncogenic types of HPV found that current smoking was associated with a 2-fold 
increase in risk of cervical cancer (95% CI 1.2-2.8). In current smokers, there was a 
significant trend of increased risk with number of cigarettes smoked per day (p for trend 
= 0.003), but not with duration of smoking. (Shields, 2004). 
 
Socio-economic status 
Women from low socio-economic background have been shown to have an increased risk 
of developing cervical cancer. Poor access to screening is responsible for this disparity. 
Sub-standard nutritional status is another possible risk for women from impoverished 
backgrounds to develop cancer more than their affluent counterparts.  
 
A case control study conducted in Bangkok found that a high intake of foods rich in 
vitamin A, especially high-retinol foods, was associated with a reduced risk of in-situ 
disease (OR  0.09; 95%CI 0.02-0.5) (Shannon, 2002). A literature review conducted by 
Garcia-Closas (2005) found no convincing evidence for an association between diet and 
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nutritional status and cervical carcinogenesis. But, this review found some biologically-
credible association between fruits and vegetable intake and HPV clearance. There is 
some support for the hypothesis that antioxidant nutrients may play a protective role in 
cervical carcinogenesis. However, current available evidence for an association between 
diet, nutritional status and cervical HPV carcinogenesis is not yet convincing. 
 
Cervical cancer is a preventable disease: 
Primary prevention of cervical cancer 
Condoms are effective in preventing HIV and other STI, but not HPV. Condoms’ failure 
to prevent HPV is linked to the fact that HPV is highly transmissible and can be passed 
by skin-to-skin contact with any HPV-infected area not covered by the condom. 
Condoms do reduce the risk of developing cervical cancer.  (American Cancer Society, 
2005b). Condom use was shown to be associated with higher rates of regression of 
cervical intraepithelial neoplasia and clearance of cervical HPV infection in women and 
with HPV-associated penile lesions in men (Holmes, 2004). 
 
A meta-analysis of twenty studies was conducted to determine whether condom use 
prevents genital HPV infection and HPV-related conditions or not. This analysis found 
inconsistent evidence that condom use reduces the risk of becoming HPV DNA-positive 
(Manhart, 2002). It is therefore likely that the relationship between condoms and reduced 
cervical cancer prevalence is linked to condom’s ability to prevent the other STI, which 
are cofactors in the development of cervical cancer once HPV infection has occurred. 
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Other promising primary prevention strategies are vaccines, microbicides that are 
effective against HPV and male circumcision (MC). A review paper on HPV vaccines 
reported on a bivalent vaccine which incorporates HPV-16 and -18 and a quadrivalent 
vaccine formulated to protect against genital wart-causing HPV-6 and -11 and HPV-16 
and -18. Both these vaccines were shown to be safe and over 90% efficacious in 
preventing HPV infections and pre-cancerous lesions (Ault, 2006). Microbicides are 
novel products that prevent STI in vitro. They are currently in phase 3 clinical trials. 
Since first generation microbicides will be non-specific, they may be more likely, than 
subsequent generations, to be active against HPV. In a review by MC has been shown to 
be about 48-60% efficacious in preventing HIV acquisition in men. Its role in preventing 
HPV has yet to be confirmed. 
 
Secondary prevention of cervical cancer 
Secondary prevention using Pap smear screening is currently the cornerstone of current 
cervical cancer prevention programmes. It relies on detecting sub-clinical changes in 
populations at risk of developing cervical cancer, and then treating these abnormalities to 
prevent progression to an advanced stage. The Bethesda System (TBS) is the most widely 
used system for describing cervical smear cytology results. This system was developed in 
1988 and was last revised in 2001. The three main categories in TBS are shown in box 1 
below (Apgar, 2003). 
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Box 1: Three main categories in the TBS: 
1. Negative for intraepithelial lesion or malignancy: this category means that no signs of 
cancer or precancerous changes or other significant abnormalities were found. 
2. Epithelial cell abnormalities: the cells of the lining layer of the cervix show changes 
that might be cancer or precancerous condition. This category is divided into several 
groups for squamous cells and glandular cells. The epithelial cell abnormalities for 
squamous cells are called: 
• Atypical squamous cells (ASC). ASCs are further divided into ASCUS (atypical 
squamous cells of unknown significance) and ASCH (atypical squamous cells, 
cannot exclude high-grade squamous intraepithelial lesions) 
• Low-grade squamous intraepithelial lesions (LSILs) 
• High-grade (H) SILs: these are more likely than LSILs to develop into cancer if 
they are untreated. 
• Squamous cell carcinoma: this shows that the woman is likely to have an invasive 
squamous cell cancer. 
3. Other malignant neoplasms: these can be uncommon forms of cancer and affect cervix 
very rarely (Fonn, 2002). 
 
Cervical cancer screening procedures using cytology, especially follow-ups and costs 
associated with cytology, limit access to screening. Laboratory processing, sample 
transport and patient time account for a significant proportion of total cervical cancer 
screening costs in developing countries (including South Africa) Goldhaber (2006). 
Alternative methods of cervical cancer screening have been implemented, especially in 
low-resourced countries. These methods include: naked eye visual inspection of the 
cervix uteri after applying diluted acetic acid (VIA), or Lugol’s iodine (VILI) or with a 
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magnifying device (VIAM). Other settings also test for human papillomavirus DNA 
using high risk probe of the Hybrid Capture-2 assay (HC2). 
 
In a study of 2944 women aged 35-65 years in Cape Town, direct visual inspection with 
acetic acid and HPV DNA testing identified similar numbers of high grade squamous 
intra-epithelial lesions and invasive carcinoma cases as Pap smear did, but with lower 
costs (Denny, 2000). Goldie (2005) showed that very cost-effective strategies in South 
Africa are those that require the fewest visits (such as HPV DNA testing).  
 
A meta-analysis of 11 studies, conducted in Africa and India, was undertaken to assess 
the accuracy of five cervical cancer screening tests (VIA, VILI, VIAM, Pap smear and 
HC2). All participants underwent colposcopy examination and abnormal colposcopy 
patients had punch biopsies taken.  Visual tests and colposcopy were highly correlated. 
Sensitivity and specificity for the visual tests were over 79% and 84%, respectively. 
Sensitivity and specificity for Pap smear was 57% and 93%, respectively and HC-2 test 
showed a sensitivity of 62% and a specificity of 94%. 
 
South African screening guidelines recommend that each woman receives three Pap 
smear screenings in her lifetime, with a ten-year interval between smears, commencing at 
not earlier than age 30 years (National Department of Health-SA, 1997). This screening 
programme was introduced in year 1997 and uses age as a risk factor for cervical cancer, 
because mild dysplasia normally regresses spontaneously in younger women and cervical 
cancer takes in excess of ten years to develop.  
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Cervical cancer incidence has declined in high income countries where populations at 
risk have access to high quality cervical screening programmes (Kitchener, 2006). South 
Africa, like many other low to middle income countries, has not succeeded in controlling 
cervical cancer mainly because the screening programme has not been implemented 
successfully and programme coverage remains low in these countries, as depicted by 
figure 4 below. However, within South Africa, mortality has declined in populations that 
have had better access to services historically (white females), compared to South 
African coloured women (Nel, 1994 and Bailie, 1996). This further highlights disparity 
between under- and adequately-resourced settings within the country. 
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Figure 4: Cervical cancer screening coverage, women aged 25-64years (Gakidou, 2008) 
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Statement of the problem 
Cervical cancer is the most common cancer in South African female population. It is 
caused by persistent HR-HPV infection interacting with certain factors. Currently South 
Africa relies on the screening programme to detect and manage pre-cancerous lesions, 
and this programme recommends screening based on the woman’s age as a risk indicator. 
There is little data on prevalence of abnormal smears in South Africa population, 
especially in the younger age group, outside of Western Cape. 
  
Rationale for this study 
Evidence from previous studies is unclear and inconsistent about risk factors associated 
with abnormal cervical cytology and development of cervical cancer. The present study 
provides analysis of association between selected risk factors and abnormal cervical 
cytology, in a population of young women (18-35 years old) at risk for HIV and other 
STI. 
 
Since most women with HPV do not progress to develop invasive cervical cancer, 
understanding which other risk factors, in addition to age, are associated with abnormal 
cervical cytology may help improve cervical cancer screening programme by extending 
screening to women with these additional risk factors and ultimately improve existing 
cervical cancer control programme in South Africa. 
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Research question 
How common is abnormal cervical smear cytology in sexually active women from 
Soweto, aged 18-35 years, and what are the factors associated with abnormal cervical 
smear cytology results? 
1.1 Study Objectives 
Main objective 
To determine factors associated with abnormal cervical smear results in women 
participating in the Microbicide Feasibility Study. 
 
Specific objectives 
1) To estimate prevalence of abnormal cervical smears in this population. 
2) To determine socio-demographical, gynaecological and sexual behaviour factors 
associated with abnormal cervical smear cytology, in this population. 
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2.0  METHODS 
2.1 Setting 
This current protocol is a secondary analysis of data collected at an enrolment visit of a 
Microbicide Feasibility Study (MFS). MFS was a prospective cohort study conducted in 
preparation for an efficacy trial of a vaginal microbicide. The main objectives of this 
study were to estimate: HIV incidence, rate of condom use and rate of cohort retention 
over twelve months, prior to starting a phase 3 trial. Women were screened for HIV and 
pregnancy and enrolled into the study if negative for both tests. At the enrolment visit, 
participants were examined for cervical cytological abnormalities –because women with 
abnormal cervical cytology were ineligible to participate in a vaginal microbicides trial, 
swabs collected for STI, and blood drawn for Herpes simplex virus-2 and syphilis 
serology. Enrolment into the MFS study occurred from 13 January 2002 to 27 January 
2004. 
 
This study was conducted in Soweto, which is a largest peri-urban township in South 
Africa. Soweto has an estimated 305 000 households and a population of about 1,3 
million people. This township lies about 15 kilometres south west of Johannesburg City, 
and thus its name: South Western Townships. The population of Soweto is predominantly 
Black and all 11 of South Africa’s official languages are spoken in Soweto. Unemployed 
household heads make up 40% of the Soweto population, and 28% of households earn 
below R800 a month. (Loots, 2008) 
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2.2 Study design and participants 
Women were invited, from the community and from primary health care facilities, to 
come to the study site for eligibility screening and participation. Consenting participants 
were included in this analysis if they were: HIV negative aged 18-35 years, sexually 
active, using a recognised method of contraception, enrolled in the MFS and had a 
cervical cytology result. The Microbicide Feasibility Study recruited women aged 18-35 
years old, because they were deemed to be at increased risk of acquiring HIV. 
Participants also had to be on a reliable contraception, because microbicide trials aimed at 
minimising the risk of women becoming pregnant and possibly exposing foetus to a trial 
product. 
 
 Participants received transport reimbursement of R50.00 at the end of the visit. All 
participants were HIV negative because one of the objectives of the MFS study was to 
estimate HIV incidence. This is an analytical cross-sectional study of data collected 
during the enrolment visit of the MFS. 
 
2.3 Clinical procedures 
All participants gave written and signed informed consent. Socio-demographic factors, 
gynaecological factors and sexual behaviour data were collected using a structured 
questionnaire. Interviews were conducted by trained staff members in a private setting. 
Two licensed rapid tests (Abbot Determine and Unigold) were used to test for HIV 
antibodies. Medical history, general and pelvic examinations were performed at the 
enrolment visit. 
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Cervical examination included: 
1. Visual inspection of the cervix to assess for: 
 Size and shape of cervix. 
 masses noted 
 sores/ulcers  
 redness  
 oedema  
 non – menstrual bleeding, and if present , source of non menstrual bleeding e.g. – 
cervical polyp; through the cervical os; cervical ectopy. 
 cervical mucous and friability. 
2. Bimanual Examination included: 
 Palpating the cervix and noting any tenderness on moving the cervix from side to 
side. 
 Palpating both adnexae for masses and tenderness. 
 Palpating the uterus to establish its size, consistency and presence of any masses. 
When the study started, Ayers spatula (wooden spatula) were used and procedure was 
changed half-way through the study to using the cervical brush. 
Syndromic management of STI was done and all clinical assessments were carried out by 
a qualified nurse. 
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2.4 Laboratory procedures 
Swabs collected from the endocervix were assessed for Neisseria gonorrhoeae (NG) and 
Chlamydia trachomatis using a qualitative commercial PCR (Roche Amplicor ®). Swabs 
taken from the vaginal wall were cultured in Diamonds media for TV, and used to 
prepare slides for Gram stain and diagnosis of Bacterial vaginosis (BV) using Nugent’s 
criteria. Blood was collected for syphilis serology. RPR reactive specimens were 
confirmed with Treponema pallidum haemagglutination test (TPHA).  Herpes simplex 
virus-2 serology was performed using the Focus HerpeSelect type-specific ELISA. 
Laboratory tests were performed by Contract Laboratory Services (CLS), in 
Johannesburg General Hospital. 
 
2.5 Data management 
All questionnaires were checked for quality before entered into the database. Data were 
double-entered using Epi-info 6 (CDC, Atlanta, 2002). Discrepancies between first and 
second data entry were resolved. The current analysis uses data collected during the 
Microbicide Feasibility Study. Selection of risk factors and of demographics for the 
current analysis was informed by the literature review on factors which have been shown 
to be associated with cervical cancer and on possible confounders. Data was analysed 
using STATA 8.2 (StataCorp, Texas, 2005) 
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2.6 Statistical analysis 
Outcome variable: 
The main outcome of interest was abnormal cervical cytology result defined according to 
the Bethesda classification system as “Epithelial cell abnormalities”. The results of 
cervical cytology were categorized into two groups, as follows: 
1) Positive: if any of the cervical abnormalities (ASCUS, ASCH, LSIL, HSIL or 
ICC) were detected in Pap smears. This category grouped together all the above 
results because of limited sample size. 
2) Negative: if no cervical abnormalities were detected in Pap smears. 
 
Main exposure variables 
Main exposures that were explored were age, socio-economic status, cohabiting status, 
parity, contraceptive use, condom use, number of sexual partners, genital symptoms, 
current STI infection (CT, GC, TV, BV, Herpes simplex virus-2, syphilis) and history of 
STI infection. 
 
Unadjusted analysis 
Categorical variables were analysed using the number and percentages in each category 
and using the chi-squared or fishers exact test to test for association. Strength of 
association was shown using OR. 
  
Controlling for confounding 
Multiple logistic regression was used to adjust for confounding variables. Backward 
stepwise regression was used during exploratory analyses of model building. This 
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analysis began with a full or saturated model, which included all variables whose p-
values were less than 0.30, during the unadjusted analysis, or which were stated a priori. 
As a rule of thumb, a less restrictive p-value is used to include more factors initially, and 
eliminate non-significant variables from this bigger model in an iterative process 
(Hosmer, 2000). The fit of the model was tested after the elimination of each variable to 
ensure that significant variables were not excluded from the model. 
 
Likelihood ratio test was used to assess the model fit after each iterative step. The model 
building had been completed when no more variables could be eliminated from the 
model, without making the model weaker. The likelihood-ratio test was used to test the 
significance of each coefficient in the model. Likelihood-ratio test was used because it is 
more robust, compared to the Wald test, when coefficients are large or when the sample 
size is small. 
 
2.7 Ethical issues 
The main study received ethical clearance from The Wits Human Research Ethics 
Committee (HREC), with ethics reference number: M02-01-09 (appendix B).  The study 
information was explained to volunteers before they were invited to participate. 
Information discussed included: confidentiality, reimbursement and that participation was 
voluntary. All volunteers gave signed informed consent to indicate their willingness to 
participate in the study.  This secondary analysis protocol was also approved by HREC 
on 30 January 2007, with ethics reference number: M070113 (appendix B). 
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3.0  RESULTS 
3.1 Participation in the study 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Diagram showing selection of study participants 
 
 
 
 
 
Screened = 1100 
Included in the main 
analysis =570 
Passed screening/eligible 
to enrol =808 
Enrolled =752 
Failed screening 
n= 292 (26.55%) 
 
HIV positive=253 (23%) 
Pregnant =28 (2.55%) 
Excluded from main analysis =182 
(24.20%) 
 
Inadequate specimen =144 (19.15%) 
No lab results =38 (5.05%) 
Did not participate 
=56 (6.93%) 
 
(wanted more time to 
think about the study) 
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Participation rate 
Figure 5 above shows flow diagram of study participants. Most participants, 253/1100 
(23%), were screened out because they tested HIV positive. Participation was high 
amongst those who were eligible to participate, 752/808 (93.1%).  
 
Pap smear adequacy rate 
Of the 752 women who participated in the study, 182 (24.2%) were excluded from final 
analysis, because their repeat cytology specimens were either unsuitable or inadequate for 
laboratory analysis (n=144) or laboratory results were missing/lost (n=38). The adequacy 
(satisfactory) rate of the slides submitted to the laboratory for cytology was thus 80.0% 
(570/714). So, the main analysis included 570 participants. 
 
3.2 Characteristics of study participants 
The majority of participants (55.6%) were aged between18 and 24 years. The median age 
of women with abnormal cervical cytology was not different from that of women with no 
cervical cytology abnormality [22.5 years (IQR 21-27) compared to 24 years (IQR 20-
28), respectively]. As shown on table 1 below, the vast majority of participants did not 
stay with their partners (82.6%), had no income (68.8%) and had one or no child (79.2%). 
Few (8.2%) participants reported having had more than one sexual partner in the last 
three months. 
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Table 1: Characteristics of study participants. 
 
Characteristic Participants (n) % (95 CI) 
Age group (yrs): 18 to 24 
                           25 to 35 
317
253
55.6 (51.4 - 59.7) 
44.4 (40.3 - 48.6) 
Highest education attained -grade: >=12 
                                                          <12 
330
240
57.9 (53.7 - 62.0) 
42.1 (38.0 - 46.3) 
Socioeconomic status: Has income 
                                     Has no income 
392
178
31.2 (64.8 - 72.6) 
68.8 (27.4 - 35.2) 
Lives with partner: Yes 
                                No 
99
471
17.4 (14.3 - 20.7) 
82.6 (79.3 - 85.7) 
Sexual partners (concurrent): >1 
                                              <=1 
47
523
8.3 (6.1 - 10.8) 
91.7 (89.2 - 93.9) 
Current contraceptive: Hormonal 
                        Non-hormonal 
325
245
57.0 (52.8 - 61.1) 
43.0 (38.9 - 47.2) 
Parity: >=1 
             Nil 
240
327
42.3 (38.2 - 46.5) 
57.7 (53.5 - 61.8) 
Ever pregnant: Yes 
                         No 
357
213
62.6 (58.5 - 66.6) 
37.4 (33.4 - 41.5) 
Use condom for contraception: Yes 
                                       No 
194
376
34.0 (30.1 - 38.1) 
66.0 (61.9 - 69.9) 
Lower abdominal pain*: Yes 
                                       No 
91
478
16.0 (13.1 - 19.3) 
84.0 (80.7 - 86.9) 
Vaginal discharge*: Yes 
                               No 
85
484
14.9 (12.1 - 18.1) 
85.1 (81.9 - 87.9) 
Genital sores*: Yes 
                       No 
37
531
6.5 (4.6 - 8.9) 
93.5 (91.1 - 95.4) 
HSV-2  seropositive: Yes 
                                   No 
301
254
54.2 (50.0 - 58.4) 
45.8 (41.6 - 50.0) 
RPR positive: Yes 
                        No 
15
540
2.7 (1.5 - 4.4) 
97.3 (95.6 - 98.5) 
GC positive: Yes 
                      No 
8
518
1.5 (0.7 - 3.0) 
98.5 (97.0 - 99.0) 
CT positive: Yes 
                      No 
60
467
11.4 (8.8 - 14.4) 
88.6 (85.6 - 91.2) 
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Characteristic Participants (n) % (95 CI) 
BV positive: Yes 
                      No 
298
256
53.8 (49.5 - 58.0) 
46.2 (42.0 - 50.5) 
TV positive: Yes 
                     No 
28
533
5.0 (3.3 - 7.1) 
95.0 (92.9 - 96.7) 
Yeast positive: Yes 
                          No 
52
496
9.5 (7.2 - 12.3) 
90.5 (87.7 - 92.8) 
(Table 1 continued). *In the past 4 weeks. 
 
3.3 Prevalence of abnormal (ASCUS-ICC) cervical cytology 
From table 2 below, the prevalence of any abnormal cervical cytology was 6.7% (95% CI 
4.8-9.0). Pap smear results in the group LSIL to HSIL were 5.3% (95% CI 3.6-7.4). 
 
Table 2: Main outcome: prevalence of abnormal cervical cytology 
 
Cytology results Frequency % (95% CI) 
Normal 532/570 93.3 (91.0 - 95.2) 
Abnormal 38/570 6.7 (4.8 - 9.0) 
ASCUS 8/570 1.4 (0.6 - 2.7) 
LSIL 23/570 4.0 (2.6 - 6.0) 
HSIL 7/570 1.2 (0.5 - 2.5) 
Total 570 100.0 
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3.4 Factors associated with abnormal cervical cytology 
3.4.1 Unadjusted analysis 
Table 3 below summarises the results of univariate analysis. Access to income was 
associated with a lower risk for cervical abnormality (OR 0.68; 95% CI 0.33-1.44). Also, 
cohabiting was associated with a lower risk for cervical abnormality (OR 0.54; 95% CI 
0.14-1.57). However, in both these instances, this protection was not statistically 
significant. None of the other demographic factors were associated with abnormal 
cervical cytology. 
 
Table 3: Factors associated with abnormal cytology results, unadjusted analysis. 
 
Risk factor Women with 
abnormal cells 
No     (%) 
Women with 
normal cells 
No     (%) 
Crude OR  
(95% CI) 
Age group (years): 18 to 24 
                               25 to 35 
24 (63.2)  
14 (36.8) 
293 (55.1) 
239 (44.9) 
1.0 
0.72 (0.33-1.48) 
Education (years): Les than 12 
                              12 or more  
18 (47.4) 
20 (52.6) 
222 (41.7) 
310 (58.3) 
1.0 
0.80 (0.39-1.64) 
Has no income 
Has income 
15 (39.5) 
23 (60.5) 
163 (30.6) 
369 (69.4) 
1.0 
0.68 (0.33-1.44) 
Not co-habiting  
Co-habiting 
34 (89.5) 
4 (10.5) 
437 (82.1) 
95 (17.9) 
1.0 
0.54 (0.14-1.57) 
Sexual partners: 1 or nil 
                           More than 1 
35 (92.1) 
3 (7.9) 
488 (91.7) 
44 (8.3) 
1.0 
0.95 (0.18-3.21) 
Use condom for contraception:      
                                       No 
                                       Yes 
 
 
26 (68.4) 
12 (31.6) 
 
350 (65.8) 
182 (34.2) 
 
1.0 
0.89 (0.40- 1.87) 
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Risk factor Women with 
abnormal cells 
No     (%) 
Women with 
normal cells 
No     (%) 
Crude OR  
(95% CI) 
One or no child 
More than one children 
7 (18.4) 
31 (81.6) 
111 (21.0) 
418 (79.0) 
1.0 
0.85 (0.31-2.04) 
Ever been pregnant: No 
Ever been pregnant: Yes 
11 (28.9) 
27 (71.1) 
202 (38.0) 
330 (62.0) 
1.0 
1.5 (0.70-3.43) 
1Non-hormonal contraceptive 
Hormonal contraceptive use 
14 (36.8) 
24 (63.2) 
231 (43.4) 
301 (56.6) 
1.0 
1.32 (0.64-2.81) 
Abnormal vaginal discharge*:     
                                              No 
                                              Yes 
 
28 (73.7) 
10 (26.3) 
 
456 (85.9) 
75 (14.1) 
 
1.0 
2.17 (0.90-4.83) 
Lower abdominal pain*: No 
                                        Yes 
30 (78.9) 
8 (21.1) 
448 (84.4) 
83 (15.6) 
1.0 
1.44 (0.55-3.36) 
Genital sores*: No 
                        Yes 
34 (89.5) 
4 (10.5) 
497 (93.8) 
33 (6.2) 
1.0 
1.77 (0.43-5.41) 
HSV-2 : Negative 
            Positive 
12 (33.3) 
24 (66.7) 
242 (46.6) 
277 (53.4) 
1.0 
1.75 (0.82-3.92) 
Syphilis: Negative 
               Positive 
35 (97.2) 
1 (2.8) 
505 (97.3) 
14 (2.7) 
1.0 
1.03 (0.02-7.16) 
2Cervical infections: Negative 
                                 Positive 
30 (90.9) 
3 (9.1) 
435 (87.9) 
60 (12.1) 
1.0 
0.73 (0.14-2.44) 
3Vaginal infections: Negative 
                                 Positive 
15 (39.5) 
23 (60.5) 
222 (41.9) 
308 (58.1) 
1.0 
1.11 (0.54-2.33) 
(Table 3 continued). *In the past 4 weeks. 
1Non-hormonal contraception includes: no contraception, condom, IUD and diaphragm. 
2Past infections (NG and CT). 
3Current infections (BV, Yeast and TV) 
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Of the gynaecological factors analysed, the odds of having abnormal cervical cytology 
result were slightly higher for those women who reported ever being pregnant (OR 1.5; 
95% CI 0.70-3.43; p=0.267) and also for those who used hormonal contraceptives (OR 
1.32; 95% CI 0.64-2.81; p=0.429). But these associations were not statistically 
significant; p-values were 0.267 and 0.429 respectively. 
 
None of the behavioural factors were associated with abnormal cervical cytology result. 
The odds ratio of having abnormal cervical result was 0.95, 95% CI 0.18-3.21, p-
value=0.935 for participants who reported having had multiple sexual partners in the last 
three months; and was 0.89, 95% CI 0.40-1.8, p-value=0.741 for participants who 
reported using condoms as their method of contraception.  
 
Self-reported genital symptoms, in the past four weeks, were associated with having 
abnormal cervical cytology result. Participants who reported having abnormal vaginal 
discharge in the last 4 weeks were more likely to have an abnormal Pap smear result (OR 
2.17; 0.90-4.83). This association was statistically significant with a p-value of 0.042. 
Whilst reporting abdominal pain, and genital sores was associated with having abnormal 
cervical cytology result, these relationships were not statistically significant (OR 1.44; 95 
% CI 0.55-3.36; p=0.378 and OR 1.77; 95 % CI 0.43-5.41; p=0.300 respectively). 
Participants who tested positive for HSV-2 were more likely to have abnormal Pap smear 
result, But this association was not statistically significant (OR 1.75; 95% CI 0.82-3.92; 
p=0.166). None of the other laboratory-diagnosed STI were associated with abnormal 
cervical cytology result. 
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3.4.2 Adjusted analysis: multiple logistic regression 
In the saturated model, the odds of having abnormal cervical cytology result were lower 
for participants who were in the older age group (25-35 years) (adjusted OR (AOR) 0.50; 
95% CI 0.22-1.11; p=0.09). The odds of having abnormal cervical cytology result were 
higher for participants with more than one child (AOR 2.16; 95% CI 0.96-4.85; p=0.06), 
with abnormal vaginal discharge (AOR 2.09; 95% CI 0.95-4.61; p=0.07), and for those 
who tested positive for HSV-2 serology (AOR 2.13; 95% CI 0.88-4.17; p=0.10). 
However, evidence to support associations for age and HSV-2 serology was weak. 
 
Main effects model 
Table 4 below shows the final model (main effects model), after a few iterative steps 
which began with selected factors from table three above. Abnormal vaginal discharge 
and multi-parity were associated with abnormal cervical cytology result. Participants with 
abnormal cervical cytology were more likely to have an abnormal vaginal discharge 
compared to those without an abnormal discharge (AOR 2.33; 95% CI 1.07-5.06; 
p=0.03); and were also more likely to have more than one child (OR 2.21; 95% CI 1.00-
4.87; p=0.05).  
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Table 4: Factors associated with abnormal cytology results, adjusted analysis 
 
Variable Women with 
abnormal cells 
No     (%) 
Women with 
normal cells 
No     (%) 
Adjusted OR  
(95% CI) 
Age group (yrs):  18 to 24 
                             25 to 35 
24 (63.2) 
14 (36.8) 
293 (45.1) 
239 (44.9) 
1.0 
0.51 (0.24-1.10) 
1More than one child 
One or no children 
7 (18.4) 
31 (81.6) 
111 (21.0) 
418 (79.0) 
2.21 (1.00-4.87) 
Abnormal vaginal         
discharge:                  Yes 
                                   No 
 
10 (26.3) 
28 (73.7) 
 
75 (14.1) 
456 (85.9) 
 
2.33 (1.07-5.06) 
1From univariate analysis, parity was not a significant risk factor, but was included in 
multiple regression because it was stated a priori. 
 
4.0 DISCUSSION 
Worldwide, cervical cancer is second only to breast cancer when it comes to incidence of 
cancer in women. Available, but out-dated, statistics indicate that South African women 
have a high risk of developing cervical cancer. (Mqoqi, 2003) The main objective of this 
study was to determine the prevalence and factors associated with abnormal cervical 
cytology results in HIV negative women from Soweto. 
 
Prevalence of abnormal cervical smears: 
Our data show a high prevalence of abnormal cervical cytology [6.7% (95%CI 4.8-9.0), 
given the younger age of the participants. The median age of women with abnormal 
cervical cytology was not different from that of women with no cervical cytology 
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abnormality [22.5 years (IQR 21-27) compared to 24 years (IQR 20-28), respectively]. 
This prevalence rate is lower than that observed in a South African survey (Fonn, 2002) 
and it compares to an observation made in an STI clinic in Baltimore (Kanno, 2005) but 
the Baltimore population included patients over the age of 35 years. Our  
  
Factors associated with cervical cancer: 
Abnormal vaginal discharge was associated with increased risk of having abnormal 
cervical cytology result (OR 2.33, 95% CI 1.07-5.06, p=0.003). Cervical glands normally 
produce mucus-containing discharge.  When the cervix has an infection or a lesion, 
inflammation occurs. Inflammation is a non-specific physiological response to tissue 
damage caused by foreign material, like infectious micro-organism and douching. During 
inflammatory response, immune response cells (viz. phagocytes and natural killer cells) 
are recruited to the site of inflammation. These immune response cells release 
inflammatory mediators (viz. cytokines IL-6 and IL-8) (Tjiong, 1999). Also, non-specific 
protective antimicrobial oxidants are produced. But, these oxidants can also cause 
oxidative damage to host DNA, thus forming precursors for cancer. Abnormal discharge 
is then produced, which changes in either colour or texture or amount or smell.  So, 
abnormal vaginal discharge is a non specific indication of a genital infection and 
inflammatory response. Other authors have also observed association between abnormal 
vaginal discharge and abnormal cervical cytology (Greenberg, 1999) and have argued 
that this non-specific immune response to infection or inflammation better explains 
association between cervical cancer and cervical infection or inflammation. 
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Our study found an association, albeit weak, between abnormal cervical cytology and 
having more than one child (OR 2.21; 95%CI 1.00-4.87; p=0.05). Since our study 
population is relatively young, having more than one child may be an indicator of higher-
risk sexual activity, which is unprotected sex. Other studies have shown similar 
relationship between abnormal cervical cytology and multi-parity. Parity is thought to 
increase the risk of cervical cancer development through the maintenance of the 
transformation zone on the exocervix for many years, which may facilitate exposure to 
HPV. 
 
Factors not associated with cervical cancer: 
Use of hormonal contraceptives was not associated with abnormal cervical cytology 
result (OR 1.32; 95% CI 0.64-2.81; p-value=0.429). The use of hormonal contraceptive 
can cause alterations in hormone levels thus disturbing normal vaginal flora and making 
it easier for STI, including HPV, to infect the cervical lining. However, we could not find 
evidence linking hormonal contraception use and abnormal cervical cytology result. 
Other authors, including IARC studies, noted increased risk after ten years of OC use 
(Moreno, 2002). But, our results agree with what a Western Cape (South Africa) study 
observed. In this case-controlled study, authors compared risk of invasive cervical cancer 
between injectable progesterone-only users and combined estrogen/progesterone oral 
contraceptive  users and found no evidence of an increased risk, regardless of duration or 
recency of use (Shapiro 2003). 
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It is common in our population for nulliparous young women to delay initiation of 
contraception. Given the relatively younger age of our study participants, exposure to 
hormonal contraception would not have been long enough to result in the development of 
abnormal cervical cells. Also, our data reported on hormonal contraceptive, whereas the 
IARC studies and the Western Cape study looked at oral contraceptive and injectable 
progesterone, specifically. 
 
Age was also not associated with abnormal cervical cytology result. Women with 
abnormal cervical cytology result were slightly younger than those with no abnormality, 
but this difference was not statistically significant (p=0.09). Most cancers take many 
years to develop. So, how possible was it to observe a high prevalence of abnormal 
cervical cytology result in this young cohort? Increased frequency of SIL at younger age 
has been attributed to early sexual initiation and differences in the biological maturity of 
the immune system and cervix. 
 
We did not measure age of participants at sexual debut, but a national youth survey 
conducted in South Africa showed that South African youth start experimenting with sex 
at younger age. This survey found that 48% (95% CI 45-52) of youth aged 15-19 years 
old had ever had sex (Pettifor, 2004). This early age at sexual debut could account for 
some of the cervical abnormality observed in our study at a relatively younger age. 
However, observing mainly low-grade abnormalities is consistent with what would be 
expected in young women, since HPV infections peak soon after initiating sexual activity 
with normally transient infections. 
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Condom use was not associated with cervical cytology result (OR 0.89; 95% CI 0.40-
1.87; p=0.741). Condom use reporting may be unreliable or condoms do not offer reliable 
protection against HPV. The latter reason is highly-plausible because there is evidence to 
suggest that HPV can be transmitted through condom-unprotected pubic areas. The 
significance, in cervical cancer pathogenesis, of HPV acquired in this way is unclear. 
 
Limitations of the study 
Study design-related limitations: 
Since this is a cross sectional study, temporal relationship between exposures and 
outcome could not be ascertained since they were both measured at the same time. 
Therefore, this study can not show if exposure variables caused the outcome, for those 
risk factors that are not fixed. Also, the outcome of the lesions could not be assessed 
because women were not followed up. 
 
Behavioural data was self-reported. Researchers have questioned the validity of self-
reported data, because respondents often provide socially-acceptable responses 
(Weinhardt, 1998). Attempts were made to address this potential problem by matching 
interviewer and participant on age and gender; conducting interviews in private rooms 
and stressing confidentiality during the informed consent process and throughout the 
interviews; and ensuring that interviewers were trained to be non-judgmental with regard 
to the various sexual behaviours, attitudes and norms reported by the respondents. 
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Recall period may have introduced recall bias. Sexual behaviour history depended on the 
recall ability of the participants.  Recall was restricted to a period of no greater than three 
months in order to minimize this bias. 
 
Limitations specific to this study: 
Since this study is secondary analysis of data collected for another purpose –the 
Microbicide Feasibility Study, data was limited to that which was collected for the main 
study. Data on smoking was not available and controlling for HPV was not possible, 
because HPV was not measured. Variables such as contraceptive use lacked detail on 
length of use. The study was also not sufficiently powered to detect differences in more 
than one level of exposures. Because the Microbicide Feasibility Study recruited women 
aged 18-35-years old, our study population was also limited to this age group. 
 
Because of sample size limitation, cytology results ranging from ASCUS up to ICC were 
lumped together into one category (abnormal cervical cytology). An attempt was made 
during the analysis to separate the HSIL results, but this did not alter the outcome of the 
analysis. Classification bias was possible with a Pap diagnosis. Pap smear cytology has 
low sensitivity, ranging from 30-87% (Nanda, 2000), and thus gives a moderate rate of 
false negative results. Given our population prevalence of abnormal cervical cytology 
(about 5%), low sensitivity could lead to an under-estimation of prevalence through false 
negatives.  Despite this limitation, Pap smear examinations are approved by the FDA 
(FDA, 2004) and the test has been used extensively (and successfully despite lower 
prevalence) in high income countries. This method is also recommended by WHO 
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(WHO, 2008) for screening for cervical pre-cancerous lesions. We therefore found it 
reasonable to use Pap smear to assess for the outcome in our study. 
 
Non-participation bias was possible because not all recruits participated. Non-participants 
were requested three times to enrol into the study, after which researchers felt that further 
persuasion would exert undue pressure on the women and would thus be unethical. 
Enrolled participants were more likely to be slightly older than non participating women. 
Younger women may have felt at a greater risk of testing HIV-positive and decided not to 
participate. Thus generalization of results should be done with caution. However, 
participation rate in our study was good (93.1%), thus mitigating any bias that may have 
resulted from this age difference. Age was also adjusted for in the main analysis. 
 
Women who screen regularly for cervical cancer have a lower risk of developing cervical 
cancer (Brinton, 1992 and Shields, 2004). We did not collect data on participants’ 
screening history. It was therefore not possible to adjust for this potential confounder in 
our analysis. But, study participants were relatively younger than the Nationally-
recommended age for cervical screening. We therefore have no reason to think that 
screening history is an important confounder in our study. 
 
Male-partner circumcision (MC) status was not measured in our study. There is evidence 
showing that MC reduces the likelihood of HPV infection and thus of cervical cancer 
(Munoz, 1997 and Schiffman, 2003). At a population level, high prevalence of MC 
results in low prevalence of HPV and thus low prevalence of ICC. High levels of MC 
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also results in low levels of HIV and other STI, thus resulting in lower risk of 
transmitting HPV. So MC could potentially reduce prevalence of HPV and ICC. Strong 
evidence linking MC with a high (up to 60% in the Orange Farm circumcision study 
(Auvert, 2005)) reduction in risk of contracting HIV for men recently came from 
randomised controlled trials in RSA, Uganda and Kenya. In the light of this evidence, it 
would be important to study the effect of MC in the development of cervical cancer. 
 
5.0  CONCLUSIONS AND RECOMMENDATIONS 
Our study showed that LSIL abnormality is common in this population of younger 
women. An abnormal cervical cytology result was associated with abnormal vaginal 
discharge and with having more than one child.  
 
Recommendations: 
 Similar studies looking at co-factors for cervical cancer should preferably 
measure: HPV, detailed contraceptive data –such as length of use. 
 Findings from this study support current screening practice, because many LSIL 
would either regress naturally or take many years to progress into cancer. 
 
   
    
52
6.0 APPENDIX A: Summary of relevant studies of risk factors for cervical cancer development  
Author/s Year Study design Study population Main outcome Risk factors Comments 
Adam, et al. 2008 Cohort -
prospective. 
Median time to 
follow-up: 122 
days 
women attending 
colposcopy clinic at 
CHBH, Soweto, South 
Africa 
persistent 
cytologic 
abnormality 
increased risk associated with: 
HIV (self reported), CD4 
count<200cells/cubic mm 
loss to follow-up was 
high (overall)=41.3% 
Ades, et al. 2008 Case-control Montreal, Canada. 381 
cases: histologically-
confirmed CIN 2 or 
worse, referred to 
colposcopy clinic. 884 
controls: women from 
outpatient clinics with 
normal cytology 
>=CIN 2 certain HLA alleles and haplotypes 
were protective 
 
Ault 2006 Review: recent 
RCT 
Women aged 15-25 yrs. 
No history of prior 
abnormal cervical 
cytology, <=6 male 
sexual partners, 
seronegative for specific 
HPV 
persistent HPV 
(specific types) 
infection, clinical 
disease 
Intervention: HPV vaccines (16 
alone; 16 & 18; 16, 18, 6 & 11). 
Results: All 3 vaccines were highly 
efficacious (71-100%). 
Participants’ follow-ups 
were: 18-48 months 
(short). So, duration of 
vaccine-induced 
immunity is unknown. It 
is also not known if 
vaccines are HPV type 
specific or they confer 
cross immunity. 
Auvert, et al. 2005 RCT Orange Farm, South 
Africa, men, 18-24 yr old. 
HIV incidence rate Intervention: male circumcision 
(MC). Result: MC offered 60% 
(32-76) protection against HIV 
acquisition. 
Unblinded intervention. 
Bayo, et al. 2002 Case-control Mali. Hospital-based. 82 
ICC cases. 97 age-
matched controls. 
ICC HPV DNA status, parity>10: 
OR=4.8 (1.5-14.7), never 
douched: OR=17.6(4.2-74.7), re-
using home-made feminine 
napkins: OR=45.9(8.8-238.7) and 
polygamous marriage: 
OR=5.3(1.3-21.3) 
Parity was associated 
with cervical cancer, 
only when it was very 
high. 
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Author/s Year Study design Study population Main outcome Risk factors Comments 
Beral, et al. 1988 Cohort -
prospective 
UK women. OC 
users=23000. Non-
users=24000. 
Incidence & 
mortality rates 
from genital tract 
cancers. 
OC ever-users had excess ICC of 
8 per 100 000 woman-years 
compared with never-users. 
Good follow-ups 
(woman-yrs): ever-
users=257 028 & never-
users=182 866 
Buga 1998 Cross-sectional 260 University of 
Transkei students, South 
Africa 
cervical cancer 
awareness & risk 
factors 
Ever heard of cxca: 74.3%. Knew 
HPV causes cxca: 68%. Unsure if 
cxca could be prevented: 62.8%. 
Reported history of STI: 42.2%. 
Absence of barrier contraceptive: 
94.6% 
Satisfactory response 
rate: 74.3% 
Castle, et al. 2001 Case-control Women from 
Guanacaste, Costa 
Rica.<50yrs. Cases: 95 
with abnormal cytology, 
220 with HPV DNA+. 
Controls: 130 without 
HPV DNA. 
High-grade lesions 
in women who are 
HPV DNA+ 
severe cervicitis: OR=1.9 (0.9-4.1) Selection of controls 
unclear. Controls fewer 
than cases. 
Chan, et al. 2007 Cross-sectional Nicaragua. All women 
attending women's health 
programme. N=1185 
prevalence and 
risk factors of STI 
and cervical 
neoplasia. 
77% reported STI symptoms. 
7.7% had abnormal cytology 
result. Risk factors: age <30: 
OR=5.2(2.2-12.0); being 
employed: OR=2.4(1.1-5.0); STI 
symptom: OR=3.3(1.0-10.9) 
 
Fonn, et al. 2002 Cross-sectional. 
Multicentre study 
Women presenting for 
screening (N=19 686).  
age-specific 
cervical cytology 
abnormality 
Risk of cxca associated with: age 
(every increase of 1yr): 
OR=1.013(p=0.0090); parity (each 
additional birth): OR=1.076 
(p=0.0085); clinically noticeable 
cervical discharge: OR(p=0.0150) 
Diverse study 
population. Big sample 
size. 
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Author/s Year Study design Study population Main outcome Risk factors Comments 
Garcia-Closas, 
et al. 
2005 Systematic 
review of 
epidemiologic 
evidence: 10 
RCT, 5 
prospective 
studies, 3 nested 
case-control 
prospective 
studies, 15 case-
control studies 
Observational studies 
controlling for HPV 
infection published 
between: Mar1995-
Nov2003 and all RCT 
published: Jan1991-
Nov2003. All studies had 
to have a control group. 
All but 2 studies were 
done in developed 
countries -mainly U.S. 
HPV persistence 
or risk of cervical 
squamous 
neoplasia (ISC 
and ICC) 
HPV persistence: possible 
protective effect (fruits, 
vegetables, vitamin C & E, beta- & 
alpha-carotene, lycopene). 
Protective effect of cervical 
neoplasia: probable (folate, retinol, 
vitamin E and possible vegetables, 
vitamin C & B12, alpha- & beta-
carotene, lycopene). High blood 
homocysteine was probable 
associated with increased risk of 
cervical neoplasia. 
 
Ghazal-Aswald, 
et al. 
2006 Cross-sectional United Arab Emirates, Al-
Ain district. 728 women 
attending primary and 
secondary care. 
cervical smear 
abnormality 
No association with chlamydia: 
chi2=0.6, p=0.4 
Cervical abnormality: 
Low prevalence 
population (1.51% 
(0.66-2.4)) 
Jennings, et al. 1992 Cohort -
retrospective, 5-
yr period. 
Women diagnosed with 
ICC at Groote Schuur 
Hospital, South Africa. 82 
women <35yr old & 82 
women >=35yrs old. 
Incidence, grades 
of cxca & survival 
following treatment 
(surgery or 
chemotherapy). 
No difference in incidence of 
abnormal cervical cytology: 11.7% 
(women <35yrs). <35yr presented 
with earlier stages of the disease: 
p=0.0031. no difference in survival 
times: p=0.8500 
Incidence for women 
>=35yrs not shown. 
Cxca was prevalent in 
women <35yrs 
Kanno, et al. 2005 Cross-sectional: 
record-review. 
Baltimore: inner-city 
public STD clinic (2001-
2002) 
Prevalence and 
risk factors of 
abnormal cervical 
cytology. 
prevalence of abnormal cytology: 
5.7%, independently associated 
with: age (p=0.010) OR=0.64 
(0.45-0.90), genital warts 
(p<0.001) OR=7.03 (2.82-17.53), 
chlamydia(p<0.049) OR=2.04 
(1.00-4.15) 
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Author/s Year Study design Study population Main outcome Risk factors Comments 
Lancaster, et al. 1999 Cross-sectional Mpumalanga, South 
Africa. 10000 cytology 
smears, from previously 
unscreened population, 
were analysed. Results 
were compared with 
similar studies from other 
previously unscreened 
populations Pretoria 
(urban) & Transkei (rural) 
Prevalence and 
risk factors of 
abnormal cervical 
cytology. 
Prevalence of abnormal cytology: 
3% (Mpumalanga), 5% (Pretoria) 
& (Transkei). ~75% of cases were 
younger than 41yrs. 79% of cases 
with >=6 children had CIN3-ICC 
compared with 16% with only 1 
child.  
Analysis mainly 
descriptive. No adjusted 
analysis was done. 
Lehtinen, et al. 2002 Nested case-
control study 
Cases: 178 cxca, 
controls: 527. Selected 
from a 5-yr cohort study 
of 550,000 women from: 
Finland, Norway & 
Sweden. . 
Cervical 
carcinoma 
HSV-2: no association found. Authors also did meta 
analysis of 6 
longitudinal studies, 
which also showed no 
association between 
HSV-2 and cxca. 
Mangan, et al. 1997 Descriptive case 
series. 
Sexually-active 
adolescents with Pap 
smear result between: 
Jan1982-Dec1983 
(N=557) and Jan1992-
Dec1993 (N=871). 
Prevalence (and 
10-yr change) of 
abnormal cytology 
results. 
Prevalence of abnormal cytology: 
2.8% (1983) vs 11.7% (1993), with 
OR=4.7(2.7-8.3). Prevalence of 
benign cellular changes also 
increased from 8.7%(1983) to 
20.1%(1993), OR=2.7(1.9-3.8) 
 
Manhart, et al. 2002 Meta-analysis Included 20 studies 
published in English 
between: 1980-2000, 
identified in MEDLINE. 
Endpoints: HPV 
infection, HPV 
subtypes, warts, 
SIL, CIN 
Condom use: no consistent 
evidence of reduction in risk of 
becoming HPV-DNA positive. 
Conclusions not 
definitive due to 
inadequate measures of 
condom use. 
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Author/s Year Study design Study population Main outcome Risk factors Comments 
Moreno, et al. 2002 Pooled data 
from 10 case-
control studies 
Women from: Asia 
(Thailand, the 
Philippines), Africa 
(Morocco), South 
America (Brazil, Peru, 
Paraguay, Columbia) & 
Spain. Cases (ICC, ISC) 
=1853, controls (normal 
cytology) =1916. 
cervical cancer 
risk 
Oral contraceptive use. Never-
users vs.: <=5yrs of use 
OR=0.73(0.52-1.03), 5-9yrs of use 
OR=2.82(1.46-5.42), >10yrs of 
use OR=4.03(2.09-8.02) 
Diverse study 
population. Big sample 
size. 
Munoz, et al. 2002 Pooled data 
from 10 case-
control studies 
Women testing positive 
for HPV DNA, infection 
from: Asia (Thailand, the 
Philippines), Africa 
(Morocco), South 
America (Brazil, Peru, 
Paraguay, Columbia) & 
Spain. Cases (ICC, ISC) 
=1800, controls (normal 
cytology) =255. 
cervical cancer 
risk 
Association between number of 
full-term pregnancies and cervical 
squamous-cell cancer: Parity: >=7 
versus nulliparous: OR=3.8(2.7-
5.5), parity=1 or 2: OR=2.3(1.6-
3.2). 
Diverse study 
population. Big sample 
size. 
Munoz, et al. 2006 Review of 
epidemiologic 
evidence: mixed 
designs 
Studies from all over the 
world (developed and 
developing) contributed 
data. 
HPV DNA, 
abnormal cervical 
cytology/histology 
In one study, HPV DNA was 
detected in 99.7% of the cervical 
tumours leading to conclusion that 
HPV is a necessary cause of cxca. 
HPV-16, -18, -45, -31, -33, -52, -
58, and -35 (descending order) 
were responsible for about 90% of 
cxca worldwide. Conclusion: 
Established risk factors: smoking, 
long-term OC-use. HIV coinfection 
and high parity. Probable 
cofactors: HSV-2 coinfection, 
Chlamydia trachomatis 
coinfection, diet and nutrition. 
Detailed review of 
studies done by IARC 
across different 
countries using common 
study protocol and well-
validated PCR assays 
for detection of HPV 
that were carried out in 
a central laboratory. 
   
    
57
Author/s Year Study design Study population Main outcome Risk factors Comments 
Nel, et al. 1994 Record-review Cytological, histological 
and oncological records 
(of 1990) from academic 
hospitals of University of 
Orange Free State, 
South Africa. N=684 
(533=black, 151=white). 
CIN and ICC in 
black vs white 
patients 
Black women presented with a 
more advanced disease: p<0.001. 
The disease peaked at an earlier 
age in black women. 
The study is purely 
descriptive. 
Shannon, et al. 2002 Case-control Siriraj Hospital, Bangkok, 
Thailand. Women. For 
the ISC analysis: 
cases=50, controls=125. 
For the ICC analysis: 
cases=134, 
controls=384. Controls 
were identified from 
family planning or 
gynecologic clinics 
associated with the 
Siriraj Hospital. 
ISC, ICC ISC vs clinic controls: protective 
effect of: high intake of vitamin-A 
(trend OR=0.25(p<0.001) and 
retinol (trend OR=0.40(p<0.001) 
 
   
    
58
Author/s Year Study design Study population Main outcome Risk factors Comments 
Shapiro, et al. 2003 Case-control Coloured and black 
women in Western Cape, 
South Africa (Jan1998-
Dec2001). Cases=524 
(first occurrences of 
histologically-confirmed 
ICC), recruited from 
public gynecology 
oncology clinics at 
tertiary hospitals. 
Controls=1541 with a 
sub-group of 254 HPV-
positive controls, 
recruited from same 
hospitals or local 
hospitals or the 
community health 
centers. Controls were 
matched for decade of 
age, ethnicity and 
residence. 
cxca risk Injectable progestogen 
contraceptives: OR=1.0(0.8-1.3), 
combined estrogen/progestogen 
oral contraceptives: OR=0.8(0.7-
1.1). 
Authors adequately 
matched cases and also 
looked at long-term use. 
Shields, et al. 2004 Case-control: 
retrospective 
review. 
235 cases of squamous 
carcinoma. 486 controls  
HPV DNA 
seropositivity, cxca 
Increased risk of HPV DNA+ 
among controls was associated 
with: number of sexual partners, 
black race & OC use. Condom 
was protective. Reduced risk of 
cxca among HPV-exposed women 
was associated with: screening, 
black race & yeast infection. 
Increased risk in the same group 
was associated with: current 
smoking: 2-fold increase, low 
education and income, and history 
of non-specific genital infection. 
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Author/s Year Study design Study population Main outcome Risk factors Comments 
Sitas, et al. 1997 Case-control Greater Johannesburg & 
Soweto, SA, between: 
mid-1990-Dec2005. 
Black patients aged 15-
50yrs. Cases: presenting 
(for the first time) with 
cancer believed to have 
infective aetiology, 
N=588. Controls: 325 
patients with cancers 
other than those 
suspected to have 
infectious cause. 
cancers linked to 
an infective agent 
(includes cxca) 
HIV infection: no association with 
cxca OR=0.6(0.2-1.9), p=0.9. HIV 
was associated with Kaposi 
sarcoma OR=61.8(19.7-194.2), 
p<0.001 and non-Hodgkin's 
lymphoma OR=4.8(1.5-14.8), 
p=0.007 
Men included in sample 
size. These results are 
inconsistent with 
numerous studies 
linking HIV and cxca. 
Small number of cxca in 
this study may have 
contributed in this null 
finding. 
Sitas, et al. 2000 Case-control Greater Johannesburg & 
Soweto, SA, between: 
1995-Jan1999. Black 
patients aged >=18yrs. 
Cases: presenting (for 
the first time) with cancer 
believed to have infective 
aetiology and with 
cardiovascular disease, 
N=4883(females=3404). 
Controls: patients with 
cancers other than those 
suspected to have 
infectious cause and 
vascular disease, N= 
844(females=556). 
cancers linked to 
an infective agent 
(includes cxca) 
HIV infection associated with: cxca 
OR=1.6(1.1-2.3), Kaposi sarcoma 
OR=21.9(12.5-38.6), p<0.001 and 
non-Hodgkin's lymphoma 
OR=5.0(2.7-9.5), vulval cancer 
OR=4.8(1.9-12.2) 
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Author/s Year Study design Study population Main outcome Risk factors Comments 
Smith, et al. 2003 Systematic 
review of 
epidemiologic 
evidence: 28 
studies (24 
case-control 
studies, 4 
cohort). 
Total N=12 531 women 
with ICC or ISC. 16 
studies done in high 
income countries: 8 in 
USA, 8 in Europe. 
ICC, ICS Hormonal contraceptives were 
associated with ICC for all women: 
<5yrs: RR= 1.1(1.1-1.2), 5-9yrs: 
RR=1.6(1.4-1.7) and >=10yrs: 
RR=2.2(1.9-2.4). Similar pattern 
was observed with HPV positive 
women and with ICS. 
Marginal effect, but 
consistent data. Large 
sample size, narrow 
confidence intervals. 
Takac, et al. 1999 Case-control Cases: 423 patients 
undergoing conisation of 
uterine cervix at the 
Gynaecology and 
Perinatology clinic of 
Maribor Teaching 
Hospital, Slovenia. 
Controls: 108 women 
undergoing regular 
gynaecological 
investigation. 
CIN Chlamydia trachomatis: chi2=0.29, 
p>0.05. Cases were older 
(p<0.01) and were mostly 
multiparous (p<0.01) 
No confounders were 
considered in the 
analysis. 
Viikki, et al. 2000 Longitudinal 
cohort study 
19114 women attending 
mass screening in 
Finland in 1985-1990. 
Women were followed up 
until 1994. 
CIN Factors associated with cxca 
were: Trachomonas vaginalis: 
SIR=6.4(3.7-10), HPV: 
SIR=5.5(4.2-7.2) and HSV-2: 
SIR=12(2.4-34). 
Strong evidence 
reported. 
 
CXCA= cervical cancer. ICC=invasive cancer. ISC: in situ cancer. CIN=cervical intraepithelial neoplasia. RCT=randomised controlled trial. OC=oral 
contraceptive. (95%CI). SIR=standardized incidence ratios 
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7.0 APPENDIX B: ETHICS CLEARANCE CERTIFICATES 
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8.0  APPENDIX C: STUDY QUESTIONNAIRES 
 
 SCREENING FOR ELIGIBILITY (V-1A)  
 
These questions will be asked at the point of recruitment. 
 
A Office use only 
Date of interview 
 
 
 
Interviewer’s initials 
 
  
 
Form used 
1=English 2=Zulu 
3=Sotho 
 
 
 
Time interview started: 
  
 
 
 
Interviewer: Provide participant with a Participant Information Sheet, and confirm that she gives consent to be screened for 
eligibility to participate in the study after reading the following: 
Hello, my name is ________, and I work for the Reproductive Health Research Unit (RHRU) at Chris Hani Baragwanath 
Hospital in the New Nurses’ Home Building. 
 
The RHRU is conducting research on the health of women in Soweto.  We would like to know more about the rate of HIV 
infection in women in Soweto, the extent to which women in this community are able to persuade their partners to use condoms, 
and to determine the factors that might prevent the women from participating in the research for a longer period.  We would like 
you to answer a few questions of a personal nature about yourself, where you live, your partners, and your attitude to HIV 
testing. Your name will not be used on this form, and all your answers will be kept confidential.  Your participation in this 
interview is voluntary, and you are free to withdraw at any time without jeopardising the care that you usually receive at this 
clinic or any clinic in the future. 
 
I’d like you to confirm that you understand the purpose and procedures of this study, and that you give consent to continue with 
this interview. 
Verbal consent given? Circle response 
Yes 1 
No 2 End interview
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B PARTICIPANT INFORMATION  Response Instruction 
4. What is your date of birth?     
 dd/mm/yyyyy   Skip to 4b 
 Don't know 98 
  Note: Eligible if born between 1967 and 1984 
   
4a If not known, what is your age?                                                              years    
 Don't know   
       
4b Screening ID (Date of birth, initials)     
 dd/mm/yy/initials   
Fill this information in the space at the bottom of every page  
4c Can we contact you with further information on this study?                             
                                              
                                                   
 Yes 1  
 No 2 Skip to 5
 No response 99 Skip to 5
4d    
 
If yes, please give contact details 
                                     
Go to Locator
form
Interviewer:  
I will start by asking you some questions about yourself, your schooling, your home, and where you go for health care services. 
     5 What is your home language? Circle one  
 isiZulu 1  
 isiXhosa 2  
 Sesotho 3  
 North Sotho (Sepedi) 4  
 Isindebele 5  
 IsiSwati 6  
 Setswana 7  
                                                                         Xitsonga 8  
                                                                                            TshiVenda 9  
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 English 10  
 Afrikaans 11  
 Other 12  
 (Specify)    
 No response 99  
6 What is your religion? Circle that which best applies  
 Christian 1  
 Traditional African 2  
 Islam 3  
 None 4  
 Other 5  
 
 
 
Specify
  
  
 
 
 No response 99   
     7 What is the highest level of education that you have completed? Choose Grade or Standard   
 Grade     
 OR     
 Standard    
 Tertiary 93  
Did not attend school 94  
 Don't know 98   
 No response 99   
     8 Do you stay in Soweto?     
 Yes 1 
No 2 Skip to 8a 
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 If yes, specify area Choose one   
 
Braam Fischer
Chiawelo
Central Western Jabavu
Diepkloof
Dlamini
Dobsonville
Doornkop
Dube village/ext
Jabavu
Jabulane
Klipspruit west
Kliptown
Khwezi
Mapetla
Meadowlands
Merafe
Mlamlankunzi
Mofolo
Molapo
Moletsane
Moroka
Mzimhlophe
Naledi
Nancefield
Noordgesig
Orlando east/west
Phefeni
Phiri
Phomolong
Pimville
Protea
Sgodiphola
Snake Park
Tladi
White city Jabavu
Zola
Zondi
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37  
Other 38 
Specify area  
Note: Eligible if living in Soweto
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8a If you do not stay in Soweto, where do you stay?    
 
 
(Specify area)
    
 No response 99  
8b
If you stay outside Soweto, are you likely to move to Soweto in the next 12 
months?    
 Yes 1  
 No 2  
 Don't know 98  
 No response 99  
8c How long have you stayed where you are currently living?    
 years    
 Don't know 98  
 No response 99  
8d How many nights have you stayed away from home in the last month?    
 nights    
 Don't know 98  
 No response 99  
      
     9 Where do you usually go for health care services? Circle all that apply   
 Private clinic 1 Skip to 10 
 Private doctor 2 Skip to 10
 Hospital 3 Skip to 10
 Chemist 4     Skip to 10
 Traditional healer 5 Skip to 10
 Public sector clinic 6 
 Other    
 Specify    Skip to 10 
 No response 99 Skip to 10 
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9a If you go to a public clinic where do you usually go to? 
 
Circle all that apply  
 
Bophelong/Snake Park
Chiawelo
Deipkloof
Green Village
Itereleng/Dobsonville
Jabavu
Klipspruit West
Lenasia
Lilian Ngoyi
Mandela Sisulu /Phomolong
Meadowlands
Mofolo
Mofolo South
Moroka
Nokuphila /Doornkop
Orlando
Pimville
Senaone
Siphumlile/Snake Park
Tladi
Tsepisong/Doornkop
Zola
Other
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23  
 Specify
 
  
No response 99 
Note: Eligible if using Soweto primary health care clinics
   10 Describe the type of housing in which you stay 
Circle that which best applies 
(only one answer)   
 House 1  
 Room inside/outside the house 2  
 Shack 3  
 Flat 4  
 Other 5  
 Specify    
 No response 99  
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10a What is your housing made of? 
Circle that which best applies 
(only one answer)   
 Bricks 1  
 Corrugated iron 2  
 Wood 3  
 Mud 4  
 Grass 5  
 Prefabricated 6  
 Other 7  
 
 
Specify
 
  
  
 
 
 No response 99  
10b How many rooms are there in your house?    
 Number    
 No response 99  
10c How many adults (persons over the age of 18) live there with you?    
 Number    
 No response 99  
10d How many children (persons under the age of 18) live there with you?    
 Number     
 No response 99   
11 Do you have a source of income?     
 Yes 1   
 No 2 Skip to 12
 No response 99  Skip to 12
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11a If YES, where or who is your income from? Circle that which best applies 
 Own salary or earnings (working) 1  
 Parent(s) (father/mother) 2 Skip to 12
 Partner (husband/boyfriend) 3 Skip to 12
 Sibling (brother or sister) 4 Skip to 12
 Government grant 5 Skip to 12
 Donations 6 Skip to 12
 Relative(s) 7 Skip to 12
 Other 8 Skip to 12
Specify  
 No response 99   
11b What job(s) do you do? Circle that which best applies 
 Employed full time 1  
 Employed part time 2  
 Self employed 3  
 Unemployed 4  
 Student/scholar 5  
 Other 6  
 Specify    
 No response 99  
Interviewer: Now I’d like to ask you some questions about you and your sexual partner or partners.  I’d like to remind you 
that this information is confidential.  
12 
Are you currently married (traditional or legal) or living with a man/woman 
with whom you have a sexual relationship? Circle that which best applies 
 Currently married, living with spouse 1 Skip to 12b
 Currently married, living with other sexual partner 2 Skip to 12b
 Not married, living with sexual partner 3 Skip to 12c
 Currently married, not living with spouse or any other sexual partner 4 Skip to 12d
 Not married, not living with sexual partner 5 Skip to 12d
 No current partner (single) 6 
 No response 99  
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12a
If no current partner (single), do you expect to be sexually active in the next 
year (12 months)  
Yes 1 Skip to 14
No 2 Skip to 14
Don’t know/unsure 98 Skip to 14
No response 99 Skip to 14
Note: Eligible is sexually active or planning to be sexually active in the next 12 months.
12b Does your spouse have any other wives that you know of?     
 Yes 1  
 No 2  
Don’t know/unsure 98 
 No response 99  
12c
How many nights did your partner spend away from home in the last month
(30 days)?     
 Nights   Skip to 13 
12d
How many days/nights in the last month (30 days) did you spend with your 
partner?     
 Nights     
   
13
Do you have any other sexual partner/s currently (apart from your spouse 
and/or the sexual partner you live with)?     
 Yes 1   
 No 2 Skip to 14 
 No response 99 Skip to 14 
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13a If YES, how many?     
 Number of other partners     
 No response 99  
13b
How many days or nights a month in total do you spend with this other 
sexual partner?    
 Use additional space if more than one other sexual partner currently    
 days/nights    
 days/nights    
 days/nights    
 No response 99  
Interviewer:  
I’m now going to ask you some questions about your pregnancies, children and family planning history.  
14 How many pregnancies have you had?    
 Number   
If zero (0),
Skip to 16
 No response 99   
15 How many living children do you have?    
 Number     
 No response 99   
     
16 Do you wish to have children/more children?    
 Yes 1  
 No 2 Skip to 17 
Don’t know/unsure 98 Skip to 17
 No response 99 Skip to 17 
16a If YES, in the next 2 years?    
 Yes 1  
 No 2 Skip to 17
 No response 99 Skip to 17 
16b If YES, in the next year?                                                                            Yes 1   
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 No 2  
 No response 99  
       
17 What contraceptive method are you using currently? Circle all that apply   
 Injectable 1 Skip to 17a 
 Pill 2  
 Loop/intrauterine device 3   
 Condom 4  
 Natural methods 5  
 None 6  
 Other 6  
 Specify    
 No response 99  
17a If you are using an injectable contraceptive, what is the name of that injectable contraceptive? 
Nur-Isterate 1 
Depo-Provera 2 
Don’t know 98 
No response99  
 
Interviewer:   
I’d like to ask you some questions about your feelings regarding HIV testing.  
18 Have you ever been tested for HIV?                                                          Yes 1  
 No 2  
 No response 99  
      
19 Are you willing to be tested for HIV?                                                          Yes 1  
 No 2 Skip to 19 b
Don’t know/unsure 98 Skip to 20 
 No response 99  Skip to 20
 Note: Eligible if agrees to be tested for HIV
19a If YES, why?  Circle all that apply  
 Don't always use a condom 1  
 Don't trust sexual partner 2  
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 Have a new sexual partner 3  
 Sexual partner has or had an STI 4  
 Want to know my HIV status 5  
 Having a baby 6  
 Do not expect a positive result 7  
 No reason 8  
 Other 9  
 Specify    
 No response 99  
19b If NO, why not?  Circle all that apply  
 Only one partner 1  
  Trust my partner 2   
  Use condoms all the time 3   
  Afraid 4   
  Don't have an STI 5   
  No reason 6   
  Other 7   
  Specify     
  No response 99   
20 Do you think that you are at risk of being infected with HIV?    
 Yes 1  
 No 2 Skip to 20b
Don’t know/unsure 98 
 No response 99  
   
20a
 
If YES, why? 
  
Circle all that apply  
 Don't trust my partner 1  
 Have more than one partner 2  
 Don't use condoms all the time 3  
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 Could be raped at any time 4  
 Have had an STI 5  
 I am not in good health 6  
 Other 7  
 Specify    
 No response 99  
20b If NO, why?  Circle all that apply  
 Abstaining from sex 1  
  Always use condoms 2  
  Only have one partner 3  
  Trust partner 4  
  Have not had an STI 5   
  I am in good health 6   
  Other 7   
  Specify     
  No response 99   
 21  Are you currently enrolled in any other research studies?     
 Yes 1  
 No 2  
 No response 99  
     Note: Not eligible if currently enrolled in any other research studies 
   
   
   
   
C INTERVIEWER CHECK FOR ELIGIBILITY  
21a Age 18-35 (Q4)  
Yes 1 
No 2 
21b Lives in Soweto (Q8)  
Yes 1 
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No 2 
21c Planning to be sexually active in the next 12 months (Q12)  
Yes 1 
No 2 
21d Using a reliable method of contraception (Q17)  
Yes 1 
No 2 
21e Willing to be tested for HIV (Q19)  
Yes 1 
No 2 
21f Not currently enrolled in any other research studies  
Yes 1 
No 2 
 
If the answer to all the above questions is YES,  
then the participant if ELIGIBLE. 
 
 
If any of the answers is NO,  
then the participant is INELIGIBLE. 
 
IF ELIGIBLE, 
 
“Thank you for answering these questions.  We would like 
to invite you to come to our clinic on the 1st Floor, New 
Nurses Home, Chris Hani Baragwanath Hospital for a follow 
up visit some time in the next two weeks when it is 
convenient for you.  Please take a copy of this information 
sheet home with you to read, and discuss with your family, 
if you wish.  We look forward to seeing you at the clinic.” 
 
IF NOT ELIGIBLE, 
 
“Thank for taking the time to answer these questions.  If 
you have any further questions about the study, please 
contact us on the numbers provided on the information 
sheet.” 
 
 
Time interview completed: 
  
 Initials 
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ENROLMENT INTERVIEW FORM (V0A)    
  
 
These questions will be asked within 30 days of screening visits V-1A and V-1B being completed. 
A Office use only    
   
1. Date of interview      [  ] [  ]/[  ] [  ]/[  ] [  ] [  ] [  ]    
                                     d   d / m  m /  y    y   y    y   
 
2.  Interviewer's initials  [   ] [   ] [   ]    
     
3.  Enrolment ID  [  ] [  ] /[  ] [  ]/ [  ] [  ] [  ] [  ]/[  ] [  ] [  ]/[  ] [  ] [  ] [  ]   
                          d    d  /  m  m  / y   y    y    y / initials  /unique number   
       
 Interviewer:    
  
 
Hello, my name is ______________, and I am from the Reproductive Health Research Unit.  We would like 
to ask you some questions about your relationships, sex life, condom use & contraceptive use. We would 
like to ask these questions so that we can understand how people's relationships work. Please remember 
that any information you give me will be handled with strict confidentiality, which means no one else will 
know about your answers. If you don’t want to answer any of these questions, please say so and I will go on 
to the next question. 
 
 B 
 
 
 
 
 Relationships 
 
Please can you confirm that your relationship status has not changed 
since your last interview. 
     
4. 4
Are you currently married (traditional or legal) or living with a 
man/woman with whom you have a sexual relationship? 
Circle that which 
best applies   
  Currently married, living with spouse 1  
  Currently married, living with other sexual partner 2  
  Not married, living with sexual partner 3  
  Currently married, not living with spouse or any other sexual partner 4 Skip to 5 
  Not married, not living with sexual partner 5 Skip to 5 
  No current partner (single) 6 Skip to 5 
  No response99 Skip to 5 
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4a 
Does your spouse or partner have any other wives or partners that 
you know of?    
 Yes1  
 No2  
 No response3  
5.  Have you had sex in the last three months?   
 Yes1 Skip to 6 
 No2  
 No response99 Skip to 6 
5a. 
If you have not had sex in the last three months, can you tell me the 
reason why?   
 Abstinence following delivery1 Skip to 9 
 Chose abstinence2 Skip to 9 
 Sick3 Skip to 9 
 No partner4 Skip to 9 
 Other 5 Skip to 9  
 Specify6 Skip to 9 
   
 No response99 Skip to 9 
6.  
How many sexual partners in total have you had in the last 3 months, 
including casual and once off encounters?   
 Total number of sexual partners   
 No response99 Skip to 9 
  
  7. Please can you define your relationship with each of these people, according to the following categories: 
 
 
Interviewer: please list each partner mentioned in question 6 above, and asked the 
participant to categorise according to the four categories listed below.  Please note the 
number of partners per category in the table below. 
 
 
 Main 
partner 
(Married or 
living 
together as 
spouse) 
Regular 
(Not 
married, 
not living 
together) 
Casual Other 
7a. 
Total number of partners in each category in the last 3 
months?     
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7b. 
Total number of partners in each category in the past 4 
weeks?      
  8. 
 
Interviewer: With reference to the partner you have mentioned, could you please tell me… 
  
Main 
partner 
Regular 
 
Casual Other 
8a. 
How many times did you have vaginal sex with each 
partner in the last week (7 days)? 
(Number of times)    
8b. 
How many times did you have vaginal sex with each 
partner in the last four weeks  
(Number of times)    
8c. 
Did you engage in anal sex with your partner in the last 
four weeks? 
    
 Yes1 1 1 1 
 No2  2  2 2         Skip to 9
 No response99  99  99 99       Skip to 9
  8d. 
If YES, how many times in the last four weeks did you 
engage in anal sex with your partner? 
(Number of times)     
    C 
 
Condom use  
 
 Have you ever used condom when having sex?   
9. Yes 1  
 No 2 Skip to 9b 
 No response 99 Skip to 11 
 9a. If YES, what were the reasons for using a condom? Circle all that apply  
 No reason 1 Skip to 10 
 Don’t trust partner 2 Skip to 10 
 To avoid pregnancy 3 Skip to 10 
 To avoid infection (STIs/HIV 4 Skip to 10 
 Other 5  
 Specify  Skip to 10 
   
 9b. 
If NO, what was the reason for not using a condom? 
Circle all that 
apply  
 No reason 1 Skip to 11 
 No need 2 Skip to 11 
 Did not have one 3 Skip to 11 
 Do not like them4 Skip to 11 
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 Raped 5 Skip to 11 
 Do not know about them 6 Skip to 11 
 Do not know how to use them7 Skip to 11 
 Could not afford them8 Skip to 11 
 Other 9 Skip to 11 
 Specify  Skip to 11 
    
 10.  
Main 
partner 
Regular 
 
Casual Other 
a. 
How many times in the last week did you use a 
condom with each partner? 
(Always, sometimes, never)     
b. 
How often did you use condom with each partner in 
last four weeks?  
(Always, sometimes, never)     
c. 
Did you use a condom the last time you had sex with 
each? 
    
 Yes1 1 1 1 
 No2 2 2 2 
 No response99 99 99 99 
 Do you always have condoms when you need them?   
11. Yes 1 Skip to 13 
 No 2  
 No response 3 Skip to 13 
 What keeps you from having condoms when you need them? Circle only one  
12. Ran out 1  
 Don’t know where to get them2  
 Can’t afford to buy them3  
 Clinic ran out of condoms 4  
 Don’t use condoms 5  
 Other 6  
 Specify   
    
    D 
 
Sexual hygiene practices 
   
13. 
Do you ever douche? 
By douching I mean, do you ever use liquids or solutions to cleanse 
the inside of your vagina? 
     Yes  
 No Skip to 17 
 No response Skip to 17 
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14. What liquids or solutions do you usually use for douching? 
Circle all that 
apply 
 Traditional Herbs 1 
 Vinegar 2  
 Water 3  
 Coca-cola 4  
 Detergent or washing powder 5  
 Disinfectant (Savlon, Dettol, etc) 6  
 Betadine douche bought over the counter 7  
 Soap and water (including Sunlight) 8  
 Other 9  
 Specify  
  
  
15. When do you usually douche? Circle only one 
 Before sex 1  
 After sex 2  
 Before and after sex 3  
 In the morning 4  
 In the morning and evening 5  
 Whenever I feel like 6  
 Other 7  
 Specify   
    
  
16. In the last 4 weeks how often did you douche? Circle only one 
 Every day 1 
 Every time I had sex 2 
 Sometimes (at least once in the last month but not everyday)
 Never
 Other 
 Specify
  
17. 
Do you ever insert any other products or substances into your 
vagina?   
 Yes 1  
 No 2 End 
 No response 99 End 
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18. 
In the last 4 weeks did you insert any other substances into your 
vagina?  
 Yes 1  
 No  End 
 No response  End 
  
 What products or substances did you insert into your vagina? Circle only one 
19. Towels, sponges, clothes 1 
 Toilet paper, tissues, cotton wool 2 
 Disinfectant 3 
 Snuff 4 
 Traditional herbs 5 
 Vinegar 6 
 Tampon 7 
 Other 8 
 Specify  
   
   
20 
How often in the last 4 weeks did you insert the products or 
substances you have mentioned into your vagina? Circle only one 
 Every day 1 
 During menses 2 
 After menses 3 
 Before sex 4 
 After sex 5 
 Before and after sex 6 
 Whenever I feel like it 7 
 Other 8 
 Specify
  
Thank you very much for your time and for sharing this information with us. All this information will be kept 
confidential. 
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